Key result
This review discusses the interactions between prostaglandins and cardiovascular physiology, addressing concerns regarding COX-2-specific drugs and the risk of cardiovascular events.
This review highlights the complex interactions between COX-derived prostaglandins and cardiovascular physiology, addressing safety concerns regarding cardiovascular events with COX-2 inhibitors.
Answers are grounded in this paper and cite their sources.
Urges caution with COX-2 inhibitors in patients at cardiovascular risk; leaves open precise mechanistic quantification in prospective studies.
Cyclooxygenase (COX)-2-specific drugs such as rofecoxib and celecoxib and the newer agents, etoricoxib and valdecoxib, were developed to provide a safer alternative to traditional nonsteroidal antiinflammatory drugs (tNSAIDs). These drugs have been shown significantly to reduce endoscopically visualized gastrointestinal ulcers, and one of them, rofecoxib, has demonstrated a 50% reduction in clinically important gastrointestinal outcomes compared with a tNSAID. However, COX-derived prostaglandins also have complex interactions with the cardiovascular system. This article briefly reviews our current understanding of the interactions between prostaglandins and cardiovascular physiology, and addresses some of the concerns that recently have been raised regarding coxibs and the risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Garret A. FitzGerald (2004) conducted a review in Cardiovascular risk with COX-2 inhibitors. COX-2-specific drugs (coxibs) vs. Traditional NSAIDs was evaluated. This review discusses the interactions between prostaglandins and cardiovascular physiology, addressing concerns regarding COX-2-specific drugs and the risk of cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: